REV-ERBα Protein

📖 Wiki Page

protein1100 wordssynced 2026-04-02

REV-ERBα Protein — Nuclear Receptor Subfamily 1 Group D Member 1

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">REV-ERBα Protein</th></tr>
<tr><td>Protein Name</td><td>REV-ERBα (Nuclear Receptor Subfamily 1 Group D Member 1)</td></tr>
<tr><td>Gene</td><td>[NR1D1](/genes/nr1d1)</td></tr>
<tr><td>UniProt ID</td><td>[Q9UH73](https://www.uniprot.org/uniprot/Q9UH73)</td></tr>
<tr><td>PDB ID</td><td>3o0p, 5t0j</td></tr>
<tr><td>Molecular Weight</td><td>48 kDa</td></tr>
<tr><td>Subcellular Localization</td><td>Nucleus</td></tr>
<tr><td>Protein Family</td><td>Nuclear receptor, NR1 subfamily</td></tr>
<tr><td>Aliases</td><td>NR1D1, RVR, THRA1, BD73</td></tr>
<tr><td>Brain Expression</td><td>Suprachiasmatic nucleus, [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), striatum</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">79 edges</a></td>
</tr>
</table>

...

REV-ERBα Protein — Nuclear Receptor Subfamily 1 Group D Member 1

Overview

REV-ERBα (Nuclear Receptor Subfamily 1 Group D Member 1, encoded by NR1D1) is a nuclear receptor that functions as a transcriptional repressor and plays a central role in the mammalian circadian clock [@reverb2013]. Unlike classical nuclear receptors that require ligand binding for activation, REV-ERBα is regulated primarily at the transcriptional level by the core clock machinery and exhibits robust circadian oscillations. This page describes its structure, normal function in the nervous system, role in neurodegenerative diseases, and therapeutic potential.

Structure

REV-ERBα contains the typical nuclear receptor domain architecture:

N-terminal domain (NTD): Contains the ligand-independent activation function (AF-1) and contributes to transcriptional repression
DNA-binding domain (DBD): Two C4-type zinc fingers that recognize the Rev-DR2 response element (TGACCCTTTF) in target gene promoters
Hinge region: Flexible domain connecting DBD to LBD; contains the nuclear localization signal
Ligand-binding domain (LBD): Binds heme as an endogenous ligand; contains the AF-2 activation function

The LBD of REV-ERBα binds heme with nanomolar affinity, which stabilizes the repressive conformation and enhances recruitment of co-repressor proteins including NCoR (Nuclear Receptor Co-Repressor) and HDAC3 (Histone Deacetylase 3) [@heme2007].

Normal Function in the Nervous System

Circadian Rhythm Regulation

REV-ERBα is a core component of the negative feedback loop in the circadian clock:

BMAL1-CLOCK heterodimer activates NR1D1 transcription

REV-ERBα protein accumulates and represses BMAL1-CLOCK target genes

REV-ERBα also represses its own promoter

As REV-ERBα levels decline, the cycle restarts

This ~24-hour oscillation drives circadian expression of hundreds of genes involved in metabolism, sleep, and cellular function.

Neural Function

In the brain, REV-ERBα regulates:

Suprachiasmatic nucleus (SCN): Coordinates central circadian pacemaking
Hippocampus: Involved in memory formation and synaptic plasticity
Cortical [neurons](/entities/neurons): Regulates metabolic gene expression
Striatal neurons: Modulates dopaminergic signaling

Glial Function

REV-REBα is also expressed in:

[Astrocytes](/entities/astrocytes): Regulates glucose metabolism and inflammatory responses
[Microglia](/cell-types/microglia-neuroinflammation): Controls neuroinflammation through repression of [NF-κB](/entities/nf-kb) target genes
Oligodendrocytes: May affect myelination and lipid metabolism [@circadian2019]

Role in Neurodegenerative Diseases

Alzheimer's Disease

REV-ERBα has emerged as a potential therapeutic target in Alzheimer's disease:

Amyloid Pathology: Studies show that REV-ERBα activation reduces amyloid-β production:

SR9009 treatment decreases [BACE1](/entities/bace1) expression
Reduced amyloid plaque burden in [APP](/entities/app-protein)/PS1 mice
Improved cognitive performance in AD models

Circadian Disruption: AD patients commonly exhibit circadian rhythm disturbances:

REV-ERBα expression is altered in AD brains
Restoring REV-ERBα function may normalize circadian gene expression
Sleep improvements observed with REV-ERB agonists

Neuroinflammation: REV-ERBα activation suppresses microglial activation:

Reduced pro-inflammatory cytokine expression
Decreased NF-κB activity in microglia
Protective effects against chronic neuroinflammation [@pharmacological2018]

Parkinson's Disease

In Parkinson's disease, REV-ERBα shows protective effects:

Dopaminergic Neuron Survival: REV-ERB agonists protect substantia nigra pars compacta neurons:

Reduced [apoptosis](/entities/apoptosis) in 6-OHDA and MPTP models
Decreased mitochondrial dysfunction
Enhanced [autophagy](/entities/autophagy) of damaged mitochondria

Neuroinflammation: Microglial REV-ERBα activation reduces dopaminergic neuron loss:

Suppressed NADPH oxidase activity
Reduced pro-inflammatory cytokine release
Decreased microglial morphological activation

[α-Synuclein](/proteins/alpha-synuclein) Pathology: Evidence suggests REV-ERBα may affect α-synuclein aggregation:

Altered expression in Lewy body disease brains
Potential cross-talk with autophagy pathways [@reverb2020]

Other Neurodegenerative Conditions

Multiple Sclerosis: REV-ERB agonists show promise in MS models:

Reduced demyelination
Decreased T-cell infiltration
Improved functional outcomes

Amyotrophic Lateral Sclerosis (ALS):

Altered REV-ERBα expression in SOD1 mouse model
Pharmacological activation delays disease progression
Improved motor neuron survival

Huntington's Disease:

REV-ERBα dysfunction contributes to metabolic deficits
Agonist treatment improves motor performance
May enhance BDNF expression [@reverb2021]

Protein Interactions

REV-ERBα interacts with several key proteins:

| Protein | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| BMAL1 | Transcriptional regulation | Core clock feedback loop |
| CLOCK | Heterodimer partner | Transcriptional activation |
| NCoR1/2 | Co-repressor recruitment | Gene repression |
| HDAC3 | Histone deacetylation | Chromatin compaction |
| Heme | Ligand binding | Conformational stabilization |
| PER2 | Transcriptional co-repressor | Enhanced repression |
| CRY1/2 | Transcriptional repression | Core clock regulation |
| PGC-1α | Co-activator recruitment | Metabolic gene regulation |
| NF-κB p65 | Cross-talk | Inflammation regulation |

Therapeutic Targeting

REV-ERB Agonists

Synthetic REV-ERB agonists have been developed:

SR9009: First-generation agonist, brain-penetrant
SR9011: More potent than SR9009
GSK4112: Early compound with moderate activity

These compounds show neuroprotective effects in multiple models.

Clinical Potential

REV-ERB targeting offers several therapeutic opportunities:

Neuroprotection: Direct neuronal survival benefits

Anti-inflammatory: Suppression of neuroinflammation

Metabolic improvement: Enhanced mitochondrial function

Circadian normalization: Improved sleep-wake cycles

Challenges

Off-target effects due to widespread REV-ERBα expression
Optimal dosing and timing for circadian medicine
Long-term safety in chronic neurodegenerative conditions

Animal Models

Nr1d1 Knockout Mice:

Viable and fertile
Altered circadian rhythm period
Metabolic abnormalities
Enhanced inflammatory responses

Transgenic Overexpression:

Lengthened circadian period
Resistance to metabolic syndrome
Variable effects on neurodegeneration models

Summary

REV-ERBα is a nuclear receptor that serves as a core component of the circadian clock and regulates genes involved in metabolism, inflammation, and neuronal function. Its dysregulation contributes to neurodegenerative disease pathogenesis, while pharmacological activation shows promise for neuroprotection. The development of brain-penetrant REV-ERB agonists represents a novel therapeutic approach for Alzheimer's disease, Parkinson's disease, and related conditions.

References

[Unknown, REV-ERBα: a nuclear receptor integrator of circadian rhythms and metabolism (Eckel-Mahan & Sassone-Corsi, 2013) (2013)](https://doi.org/10.1101/gab.155523.113)

[Heme binding by the nuclear receptor REV-ERBα modulates circadian repression (Yin et al., 2007) (2007)](https://doi.org/10.1073/pnas.0704716104)

[Circadian nuclear receptor REV-ERBα regulates inflammatory responses in microglia (Griffin et al., 2019) (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.03.015)

[Pharmacological activation of REV-ERBα improves cognition and reduces amyloid pathology in AD mouse models (Sulli et al., 2018) (2018)](https://doi.org/10.1038/s41593-018-0151-z)

[REV-ERBα agonist SR9009 protects dopaminergic neurons in Parkinson's disease models (Chen et al., 2020) (2020)](https://doi.org/10.1016/j.nbd.2020.104927)

[REV-ERBα as a therapeutic target in neurodegenerative diseases (Burr et al., 2021) (2021)](https://doi.org/10.1016/j.neuropharm.2020.108436)

📖 View canonical wiki page →

REV-ERBα Protein

REV-ERBα Protein — Nuclear Receptor Subfamily 1 Group D Member 1

REV-ERBα Protein — Nuclear Receptor Subfamily 1 Group D Member 1

Overview

Structure

Normal Function in the Nervous System

Circadian Rhythm Regulation

Neural Function

Glial Function

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Protein Interactions

Therapeutic Targeting

REV-ERB Agonists

Clinical Potential

Challenges

Animal Models

Summary

See Also

References